Riskpilot← Back to searchSign inGet full accessFDA Holding AB
ABActiveOrg 5591662498StockholmLegal activities · NACE 6910Est. 20181 employees
Revenue 2024
SEK 450K
-28% vs 2023
EBITDA margin
-9.7%
-111% vs 2023
Equity ratio
48.9%
Financial strength
Net profit 2024
SEK -48K
-120% vs 2023
| Revenue | SEK 450K | -28% |
| EBITDA | SEK -44K | -111% |
| Net profit | SEK -48K | -120% |
| Total assets | SEK 664K | -39% |
| Equity | SEK 324K | -43% |
| Employees | 1 | — |
Legal name
FDA Holding AB
Org number
5591662498
Legal form
Aktiebolag
NACE code
6910 · Legal activities
Founded
18 juli 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva juridisk och ekonomisk rådgivning, konsultverksamhet inom telekom, äga och förvalta aktier och andra värdepapper samt därmed förenlig verksamhet.
Address
Stockholm
Email
fredrik@prorata.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 58 | 1 209 | 0 | 625 | 450 |
| Staff expenses | — | — | — | — | −240 |
| EBITDA | −2 | 739 | −24 | 391 | −44 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −2 | 739 | −24 | 391 | −44 |
| Net financials | — | −1 | −308 | 11 | 5 |
| Profit before tax | −2 | 557 | −155 | 302 | −43 |
| Tax | −0 | −115 | −2 | −63 | −5 |
| Net profit | −2 | 442 | −157 | 239 | −48 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 92 | 1 016 | 528 | 1 084 | 664 |
| Equity | 48 | 491 | 333 | 572 | 324 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 44 | 346 | 37 | 253 | 77 |
| Total debt | 44 | 346 | 37 | 253 | 77 |
EBITDA margin
-9.7%
This company
15.8%
Market median
-161% vs market
20202024
Equity ratio
48.9%
This company
38.2%
Market median
+28% vs market
20202024
Return on equity
-14.7%
This company
18.4%
Market median
-180% vs market
20202024
Net profit margin
-10.6%
This company
8.1%
Market median
-231% vs market
20202024
Asset turnover
0.68×
This company
1.12×
Market median
-39% vs market
20202024
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2020 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2022 | |
| Chairman | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FDA Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Wilhelm Dahlborn | Deputy Board Member | 0 companies |
| Fredrik Robert Dahlborn | Chairman | 0 companies |
| Lukas Oskar Pöldma | Deputy Board Member | 0 companies |
| Rebecca Victoria M Hellkvist | Board of Directors | 0 companies |
| Linus Alfred Magnus Pöldma | Chairman | 0 companies |